Loxo Oncology intends to price its initial public sale of common stock

Cowen, Stifel, Oppenheimer and JMP Securities to assist with offering

By Devika Patel

Knoxville, Tenn., June 30 – Loxo Oncology, Inc. will price its initial public offering of common stock with a 30-day greenshoe option, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

Cowen and Co. and Stifel are the joint bookrunning managers. Oppenheimer & Co. and JMP Securities are the co-managers.

Proceeds will be used for clinical trials, research and development, working capital and general corporate purposes.

The Stamford, Conn., company develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. The company intends to list its common stock on the Nasdaq under the symbol “LOXO.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.